

Uh Athale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8730129/publications.pdf>

Version: 2024-02-01

99
papers

3,735
citations

147801

31
h-index

133252

59
g-index

101
all docs

101
docs citations

101
times ranked

4131
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. <i>Lancet Oncology</i> , The, 2010, 11, 950-961.	10.7	377
2	Postinduction Dexamethasone and Individualized Dosing of <i>Escherichia Coli</i> L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Studyâ€”Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. <i>Journal of Clinical Oncology</i> , 2013, 31, 1202-1210.	1.6	274
3	Intravenous pegylated asparaginase versus intramuscular native <i>Escherichia coli</i> l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1677-1690.	10.7	193
4	Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. <i>Blood</i> , 2001, 97, 3727-3732.	1.4	192
5	Thrombosis in children with acute lymphoblastic leukemia. <i>Thrombosis Research</i> , 2003, 111, 199-212.	1.7	175
6	Childhood Atypical Teratoid Rhabdoid Tumor of the Central Nervous System. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 651-663.	0.6	167
7	Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes. <i>Pediatrics</i> , 2012, 130, 1003-1011.	2.1	142
8	<i>Erwinia</i> asparaginase after allergy to <i>E. coli</i> asparaginase in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2010, 54, 199-205.	1.5	133
9	Thrombosis in children with acute lymphoblastic leukemia. <i>Thrombosis Research</i> , 2003, 111, 125-131.	1.7	130
10	Impact of hemochromatosis gene mutations on cardiac status in doxorubicinâ€”treated survivors of childhood highâ€”risk leukemia. <i>Cancer</i> , 2013, 119, 3555-3562.	4.1	128
11	Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. <i>Pediatric Blood and Cancer</i> , 2008, 51, 792-797.	1.5	111
12	Childhood cancers in Zambia before and after the HIV epidemic.. <i>Archives of Disease in Childhood</i> , 1995, 73, 100-105.	1.9	91
13	Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 1351-1353.	1.4	90
14	Development and validation of a generic scale for use in transition programmes to measure selfâ€”management skills in adolescents with chronic health conditions: the <i>TRANSITION</i> â€” <i>Q</i> . <i>Child: Care, Health and Development</i> , 2015, 41, 547-558.	1.7	87
15	Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. <i>British Journal of Haematology</i> , 2005, 129, 803-810.	2.5	84
16	Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. <i>Blood Advances</i> , 2018, 2, 1449-1458.	5.2	73
17	Thromboembolic Complications in Pediatric Hematologic Malignancies. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 416-426.	2.7	69
18	Thromboembolism in children with sarcoma. <i>Pediatric Blood and Cancer</i> , 2007, 49, 171-176.	1.5	59

#	ARTICLE	IF	CITATIONS
19	Genetic analysis of inherited bone marrow failure syndromes from one prospective, comprehensive and population-based cohort and identification of novel mutations. <i>Journal of Medical Genetics</i> , 2011, 48, 618-628.	3.2	55
20	Comparative analysis of Shwachman-Diamond syndrome to other inherited bone marrow failure syndromes and genotype-phenotype correlation. <i>Clinical Genetics</i> , 2011, 79, 448-458.	2.0	50
21	Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27827.	1.5	50
22	Clinical and Genetic Analysis of Unclassifiable Inherited Bone Marrow Failure Syndromes. <i>Pediatrics</i> , 2008, 122, e139-e148.	2.1	49
23	Body composition in long-term survivors of acute lymphoblastic leukemia diagnosed in childhood and adolescence: A focus on sarcopenic obesity. <i>Cancer</i> , 2018, 124, 1225-1231.	4.1	49
24	Thromboembolism in children with lymphoma. <i>Thrombosis Research</i> , 2008, 122, 459-465.	1.7	47
25	Thrombosis in children with acute lymphoblastic leukemia. <i>Thrombosis Research</i> , 2003, 111, 321-327.	1.7	44
26	Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: A correlation with cytochrome b5 reductase (Cb5R) enzyme levels. <i>Pediatric Blood and Cancer</i> , 2005, 44, 55-62.	1.5	40
27	Corticosteroids, Behavior, and Quality of Life in Children Treated for Acute Lymphoblastic Leukemia; A Multicentered Trial. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, 517-523.	0.6	39
28	Thromboembolic complications in children with cancer. <i>Thrombosis Research</i> , 2006, 118, 137-152.	1.7	36
29	Predictors of bony morbidity in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2012, 59, 77-82.	1.5	36
30	Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. <i>Journal of Clinical Oncology</i> , 2021, 39, 3496-3505.	1.6	36
31	Central Venous Line Dysfunction is an Independent Predictor of Poor Survival in Children With Cancer. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, 188-193.	0.6	34
32	Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. <i>Blood Advances</i> , 2018, 2, 529-533.	5.2	34
33	Hemorrhagic Complications in Pediatric Hematologic Malignancies. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 408-415.	2.7	31
34	Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26952.	1.5	31
35	Neurological PREsentations in Sickle Cell Patients Are Not Always Stroke: A Review of Posterior Reversible Encephalopathy Syndrome in Sickle Cell Disease. <i>Pediatric Blood and Cancer</i> , 2016, 63, 983-989.	1.5	30
36	Thrombosis in pediatric cancer: identifying the risk factors to improve care. <i>Expert Review of Hematology</i> , 2013, 6, 599-609.	2.2	29

#	ARTICLE	IF	CITATIONS
37	Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 973-982.	1.5	29
38	Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 0001 and 05001. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27256.	1.5	26
39	Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05001 and 11001. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28719.	1.5	26
40	An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05001. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26871.	1.5	23
41	Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 561-565.	0.6	22
42	Experience with ponatinib in paediatric patients with leukaemia. <i>British Journal of Haematology</i> , 2020, 189, 363-368.	2.5	21
43	Health-related quality of life in long-term survivors of acute lymphoblastic leukemia in childhood and adolescence. <i>Quality of Life Research</i> , 2017, 26, 1371-1377.	3.1	20
44	Body composition and bone health in long-term survivors of acute lymphoblastic leukaemia in childhood and adolescence: the protocol for a cross-sectional cohort study. <i>BMJ Open</i> , 2015, 5, e006191-e006191.	1.9	18
45	Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: A prospective evaluation. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26938.	1.5	18
46	Von Willebrand factor and thrombin activation in children with newly diagnosed acute lymphoblastic leukemia: An impact of peripheral blasts. <i>Pediatric Blood and Cancer</i> , 2010, 54, 963-969.	1.5	15
47	Thromboembolism Incidence and Risk Factors in Children with Cancer: A Population-Based Cohort Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1646-1655.	3.4	15
48	Fluctuations in dietary intake during treatment for childhood leukemia: A report from the DALLT cohort. <i>Clinical Nutrition</i> , 2019, 38, 2866-2874.	5.0	14
49	Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study. <i>BMC Cancer</i> , 2017, 17, 313.	2.6	13
50	Protective Effects of Dietary Intake of Antioxidants and Treatment-Related Toxicity in Childhood Leukemia: A Report From the DALLT Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 2151-2159.	1.6	13
51	How Variable Is Our Delivery of Information? Approaches to Patient Education About Oral Chemotherapy in the Pediatric Oncology Clinic. <i>Journal of Pediatric Health Care</i> , 2017, 31, e1-e6.	1.2	12
52	The development of thromboembolism may increase the risk of osteonecrosis in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1851-1854.	1.5	11
53	Fanconi Syndrome Secondary to Deferasirox in Diamond-Blackfan Anemia: Case Series and Recommendations for Early Diagnosis. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1480-1483.	1.5	11
54	Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: A report from <sc>CYP</sc>. <i>American Journal of Hematology</i> , 2021, 96, 796-804.	4.1	11

#	ARTICLE	IF	CITATIONS
55	Randomized Study of Pegaspargase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001. <i>Blood</i> , 2016, 128, 175-175.	1.4	11
56	Transfusion-related alloimmunization in children: epidemiology and effects of chemotherapy. <i>Vox Sanguinis</i> , 2016, 111, 299-307.	1.5	9
57	Body mass index and thromboembolism in children with hematological malignancies. <i>Pediatric Blood and Cancer</i> , 2012, 59, 320-322.	1.5	8
58	Iron overload in transfusion-dependent survivors of hemoglobin Bart's hydrops fetalis. <i>Haematologica</i> , 2018, 103, e184-e187.	3.5	8
59	Pyomyositis Causing Temporary Quadriplegia During Induction Therapy for Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, 223-226.	0.6	7
60	Outcomes of children with chronic myeloid leukemia: A population-based cohort study. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28491.	1.5	7
61	Results Of The DFCI ALL Consortium Protocol 05-001 For Children and Adolescents With Newly Diagnosed ALL. <i>Blood</i> , 2013, 122, 838-838.	1.4	7
62	Randomized Comparison of IV PEG and IM E. Coli Asparaginase in Children and Adolescents with Acute Lymphoblastic Leukemia: Results of the DFCI ALL Consortium Protocol 05-01. <i>Blood</i> , 2011, 118, 874-874.	1.4	6
63	Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29581.	1.5	6
64	Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohort. <i>Blood Advances</i> , 2021, 5, 451-458.	5.2	5
65	Bone health in long-term survivors of pediatric acute lymphoblastic leukemia. An assessment by peripheral quantitative computed tomography. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29218.	1.5	5
66	Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001. <i>Blood</i> , 2015, 126, 248-248.	1.4	5
67	Acute Perforative Appendicitis During Preoperative Chemotherapy for Wilms Tumor. <i>Pediatric Hematology and Oncology</i> , 2003, 20, 147-150.	0.8	4
68	Health Status and Health-related Quality of Life Measurement in Pediatric Cancer Clinical Trials: An Examination of the DFCI 00-01 Acute Lymphoblastic Leukemia Protocol. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 580-587.	0.6	4
69	Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol. <i>BMJ Open</i> , 2019, 9, e030092.	1.9	4
70	Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease. <i>Blood</i> , 2015, 126, 2613-2613.	1.4	4
71	Outcome of Acute Myeloid Leukemia in Children Adolescents and Young Adults Treated with an Uniform Protocol in Casablanca, Morocco. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 255-259.	0.6	3
72	Utilising red cell antigen genotyping and serological phenotyping in sickle cell disease patients to risk-stratify patients for alloimmunisation risk. <i>Transfusion Medicine</i> , 2020, 30, 263-274.	1.1	3

#	ARTICLE	IF	CITATIONS
73	Increasing Incidence and Prevalence of Pathologic Hemoglobinopathies Among Children in Ontario, Canada from 1991-2013. <i>Blood</i> , 2018, 132, 4698-4698.	1.4	3
74	Relationships of Bone Mineral Density to Whole Body Mass, Fat Mass and Fat-free Mass in Long-term Survivors of Acute Lymphoblastic Leukemia in Childhood. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, 12-17.	0.6	3
75	Glycemic Control in Patients Treated with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review. <i>Blood</i> , 2018, 132, 4273-4273.	1.4	2
76	Hand Mirror Cells and Hypercalcemia: A Rare Presentation of Pediatric Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e181-e184.	0.6	1
77	Transfusion-Related Iron Overload: A Covert Risk Of Supportive Cancer Care. <i>Blood</i> , 2013, 122, 3656-3656.	1.4	1
78	Favorable Risk Group Acute Myeloid Leukemia in Children and Young Adult Treated in Uniform Protocol in Casablanca, Morocco. a Preliminary Analysis. <i>Blood</i> , 2015, 126, 4891-4891.	1.4	1
79	Transition of Care Under One Roof at the McMaster Hemoglobinopathy Clinic. <i>Blood</i> , 2014, 124, 4851-4851.	1.4	1
80	Impact of ABO Blood Group on the Development of Venous Thromboembolism in Children With Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, 216-223.	0.6	1
81	Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27082.	1.5	0
82	Feasibility and safety of delivering full-dose anticoagulation therapy in children treated according to Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium therapy protocols. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27483.	1.5	0
83	Phase-specific risks of outpatient visits, emergency visits, and hospitalizations during Children's Oncology Group-based treatment for childhood acute lymphoblastic leukemia: A population-based study. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29141.	1.5	0
84	Thromboembolism in Children with Sarcoma.. <i>Blood</i> , 2005, 106, 4109-4109.	1.4	0
85	Peripartum Management of Women with Suspected Hereditary Thrombocytopenia.. <i>Blood</i> , 2007, 110, 3224-3224.	1.4	0
86	Combination of Dexamethasone and Asparaginase Induces Prothrombotic State in Children Receiving Multiagent Chemotherapy for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 3536-3536.	1.4	0
87	Outcome and Clinical Characteristics of Clonal and Malignant Myeloid Transformation in Inherited Bone Marrow Failure Syndromes. <i>Blood</i> , 2012, 120, 1266-1266.	1.4	0
88	Transfusion Related Alloimmunization In Children: Epidemiology and Effects Of Chemotherapy (TRACE-EC Study). <i>Blood</i> , 2013, 122, 1161-1161.	1.4	0
89	Red Cell Antigen Genotyping Compared to Standard Serological Phenotyping in Sickle Cell Disease Patients in Canada: Potential for Reducing Alloimmunization. <i>Blood</i> , 2015, 126, 3404-3404.	1.4	0
90	Acute Myeloid Leukaemia in Children: Preliminary Results of a National Protocol in Casablanca, Morocco. <i>Blood</i> , 2015, 126, 4898-4898.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Effect of Asparaginase and Dexamethasone on FVIIa-at Complex and F1.2 in Children with Acute Lymphoblastic Leukemia: Evidence of Hypercoagulable State. <i>Blood</i> , 2015, 126, 3552-3552.	1.4	0
92	Anticoagulation Therapy for Thrombotic Events in Paediatric Cancer Patients with Low Platelet Counts. <i>Blood</i> , 2016, 128, 2625-2625.	1.4	0
93	Evaluation of Mortality during Treatment of Acute Myeloid Leukemia in Patients According to Morocco National AML-MA-2011 Protocol in Casablanca. <i>Blood</i> , 2016, 128, 5177-5177.	1.4	0
94	Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001. <i>Blood</i> , 2016, 128, 761-761.	1.4	0
95	Elucidating the Thrombogenic Risk of Non-O Blood Groups in Children with Acute Lymphoblastic Leukemia (ALL): Is Von Willebrand Factor a Culprit ?. <i>Blood</i> , 2016, 128, 4990-4990.	1.4	0
96	Outcome of acute Myeloid Leukemia in Adults Patients Treated According to Morocco National AML-MA-2011 Protocol in Casablanca, Morocco. <i>Blood</i> , 2016, 128, 5173-5173.	1.4	0
97	Outcome of Acute Myeloid Leukemia in Children and Young Adults Treated with an Uniform Protocol in Casablanca, Morocco. <i>Blood</i> , 2016, 128, 5176-5176.	1.4	0
98	Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium. <i>Blood</i> , 2016, 128, 1729-1729.	1.4	0
99	Genetic Ancestry and Skeletal Toxicities Among Childhood Acute Lymphoblastic Leukemia Patients in the DFCI 05-001 Cohort. <i>Blood</i> , 2019, 134, 3811-3811.	1.4	0